NCT07856017 Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
| NCT ID | NCT07856017 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Prostate Cancer (Adenocarcinoma) |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-07-21 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2026-07-21 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥55 years; 2. Indication for prostate biopsy; 3. Availability of total prostate-specific antigen (tPSA), free PSA (fPSA) levels, and multiparametric MRI (mpMRI) results within 1 month prior to biopsy. Exclusion Criteria: 1. Pathological diagnosis of malignancies other than prostatic acinar adenocarcinoma; 2. Concomitant malignant tumors potentially affecting imaging findings (e.g., rectal, bladder, or testicular cancer); 3. Cachexia or organ function decompensation.
Frequently Asked Questions
Who can join the NCT07856017 clinical trial?
This trial is open to male participants only, aged 55 Years or older, studying Prostate Cancer (Adenocarcinoma). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07856017 currently recruiting?
Yes, NCT07856017 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shanghai Zhongshan Hospital to inquire about joining.
Where is the NCT07856017 trial being conducted?
This trial is being conducted at Shanghai, China, Shanghai, China, Shanghai, China, Shanghai, China.
Who is sponsoring the NCT07856017 clinical trial?
NCT07856017 is sponsored by Shanghai Zhongshan Hospital. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.